Investor Alert

New York Markets Close in:

Oct. 19, 2021, 7:34 a.m. EDT

J&J's COVID-19 shot generated $502 million in sales in the third quarter

Shares of Johnson & Johnson (NYS:JNJ) were up 0.1% in premarket trading on Tuesday after the company said it brought in $502 million in worldwide sales of its COVID-19 vaccine in the third quarter of 2021 as part of its earnings report. That adds up to a total of $766 million in sales of its COVID-19 shot so far this year. J&J's stock is up 1.7% for the year, while the broader S&P 500 (S&P:SPX) has gained 19.4%.

Link to MarketWatch's Slice.